Colorectal cancer
Conditions
Interventions
experimental group:Capecitabine 500mg po bid
Sponsors
Zhongshan Affiliated Hospital, Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female, aged from 18 to 70 years; 2. Pathologically diagnosed as colorectal adenocarcinoma; 3. At the time of initial diagnosis, enhanced CT or MRI showed that the clinical stage of colon cancer was stage IV with liver and/or lung metastasis, and R0 resection or radiofrequency ablation was performed on the primary tumor and metastatic lesions, the perioperative chemotherapy was completed, and the CT or MRI examination reached NED(No evidence of disease) within 4 weeks before enrollment; 4. ECOG PS 1-2; 5. There were no other underlying diseases affecting organ function; 6. Understand, be willing to give consent, and sign the written informed consent form prior to undergoing any study-specific procedure.
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with more than one malignancy; 2. Pregnant or lactating women; 3. Patients with mental illness; 4. Combined with coronary heart disease, myocardial infarction, renal failure, pulmonary embolism and other diseases that may affect the survival of patients; 5. Patients with poor compliance can not cooperate with the treatment; 6. There is a known deficiency of dihydropyrimidine dehydrogenase (DPD), or Capecitabine intolerance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, OS; | — |
Countries
China
Contacts
Public ContactFang Cantu
Zhongshan Affiliated Hospital,Guangzhou University of Chinese Medicine
Outcome results
None listed